Dehydroepiandrosterone: physiological role, therapeutic effects, potential use in dentistry

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Dehydroepiandrosterone (DHEA) is a steroid hormone produced in the zona reticularis of the adrenal cortex. DHEA underproduction is frequently associated with age-related diseases such as cancer, atherosclerosis, Alzheimer's disease, cardiovascular diseases, etc.

AIM: To summarize available data on metabolism, DHEA biochemical and physiological mechanisms of action, therapeutic potential in treatment of age-related diseases and to discuss potential use in dentistry.

MATERIALS AND METHODS: Four electronic databases (PubMed, ScienceDirect, Google Search, and eLIBRARY.RU) were searched from 2000 to 2024. Based on the selection criteria, 45 publications were included. They were focused on physiological role of DHEA in the body, pharmacological effects observed with DHEA products, and the effect of age-related decrease in DHEA on pathological changes in the human body. The publications covered in vitro and in vivo study results (including randomized and controlled) and literature reviews. The methodology meets the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) requirements for systematic reviews and meta-analysis.

RESULTS: The publications provided the results of scientific researches of DHEA chemical structure and neurophysiologic effects, production at different age periods, DHEA biological and therapeutic effects on the human body, and current synthesized pharmaceutical forms.

CONCLUSION: This systematic review showed DHEA therapeutic potential in geriatric dentistry and warranted further research.

Full Text

Restricted Access

About the authors

Igor S. Kopetsky

The Russian National Research Medical University named after N.I. Pirogov

Author for correspondence.
Email: kopetski@rambler.ru
ORCID iD: 0000-0002-4723-6067
SPIN-code: 8813-9525

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

Olga Yu. Guseva

The Russian National Research Medical University named after N.I. Pirogov

Email: o-guseva@bk.ru
ORCID iD: 0000-0002-9365-4040
SPIN-code: 1414-5643

MD, Cand. Sci. (Medicine)

Russian Federation, Moscow

Tamara G. Tsagaraeva

The Russian National Research Medical University named after N.I. Pirogov

Email: t_tsagaraeva@mail.ru
ORCID iD: 0009-0007-4262-8161
SPIN-code: 1070-2261
Russian Federation, Moscow

References

  1. Klinge CM, Clark BJ, Prough RA. Dehydroepiandrosterone research: past, current, and future. Vitam Horm. 2018;108:1–28. doi: 10.1016/bs.vh.2018.02.002
  2. Rozhivanov PV, Vaks VV. Dehydroepiandrosterone: physiological role and possibilities of use as a drug. Problems of Endocrinology. 2005;51(2):46–51. EDN: SSVXFC doi: 10.14341/probl200551246-51
  3. Goncharov NP, Kacija GV. Dehydroepiandrosterone biosynthesis, metabolism, biological effects, and clinical use (analytical review). Andrology and Genital Surgery. 2015;16(1):13–22. EDN: TRZITV doi: 10.17650/2070-9781-2015-1-13-22
  4. Webb SJ, Geoghegan TE, Prough RA, Michael Miller KK. The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab Rev. 2006;38(1-2):89–116. doi: 10.1080/03602530600569877
  5. Leimola-Virtanen R, Salo T, Toikkanen S, et al. Expression of estrogen receptor (ER) in oral mucosa and salivary glands. Maturitas. 2000;36(2):131–137. doi: 10.1016/s0378-5122(00)00138-9
  6. Aliev AD. Estrogen receptors in women with oral mucosal cancer. Biomedicina (Baku). 2006;4:22–24. (In Russ.)
  7. Sahu P, Gidwani B, Dhongade HJ. Pharmacological activities of dehydroepiandrosterone: A review. Steroids. 2020;153:108507. doi: 10.1016/j.steroids.2019.108507
  8. Nuralieva NF, Jukina MYu, Troshina EA, Platonova NM. Ndrogen deficiency in women with adrenal insufficiency. Dehydroepiandrosterone. Review. Gynecology. 2018;20(4):35–39. EDN: UZCWIW doi: 10.26442/2079-5696_2018.4.35-39
  9. Dismukes AR, Meyer VJ, Shirtcliff EA, et al. Diurnal and stress-reactive dehydroepiandrosterone levels and telomere length in youth. Endocr Connect. 2016;5(3):107–114. doi: 10.1530/EC-16-0007
  10. Wang Q, Wang X, Liu B, et al. Aging induces region-specific dysregulation of hormone synthesis in the primate adrenal gland. Nat Aging. 2024;4(3):396–413. doi: 10.1038/s43587-024-00588-1
  11. Ladang A, Beaudart C, Reginster JY, et al. Correction: Biochemical markers of musculoskeletal health and aging to be assessed in clinical trials of drugs aiming at the treatment of sarcopenia: consensus paper from an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d'Expérimentation en Santé (CARES SPRL), under the auspices of the World Health Organization Collaborating Center for the epidemiology of musculoskeletal conditions and aging. Calcif Tissue Int. 2023;113(3):357–358. doi: 10.1007/s00223-023-01114-y
  12. Skare TL, Hauz E, de Carvalho JF. Dehydroepiandrosterone (DHEA) supplementation in rheumatic diseases: a systematic review. Mediterr J Rheumatol. 2023;34(3):292–301. doi: 10.31138/mjr.20230825.dd
  13. Mendoza-Milla C, Valero Jiménez A, Rangel C, et al. Dehydroepiandrosterone has strong antifibrotic effects and is decreased in idiopathic pulmonary fibrosis. Eur Respir J. 2013;42(5):1309–1321. doi: 10.1183/09031936.00027412
  14. Nakashima N, Haji M, Sakai Y, et al. Effect of dehydroepiandrosterone on glucose uptake in cultured human fibroblasts. Metabolism. 1995;44(4):543–548. doi: 10.1016/0026-0495(95)90065-9
  15. Aoki K, Terauchi Y. Effect of dehydroepiandrosterone (DHEA) on diabetes mellitus and obesity. Vitam Horm. 2018;108:355–365. doi: 10.1016/bs.vh.2018.01.008
  16. Li L, Yao Y, Zhao J, et al. Dehydroepiandrosterone protects against hepatic glycolipid metabolic disorder and insulin resistance induced by high fat via activation of AMPK-PGC-1α-NRF-1 and IRS1-AKT-GLUT2 signaling pathways. Int J Obes (Lond). 2020;44(5):1075–1086. doi: 10.1038/s41366-019-0508-8
  17. Yang Q, Mao Q, Liu M, et al. The inhibitory effect of dehydroepiandrosterone and its derivatives against influenza A virus in vitro and in vivo. Arch Virol. 2016;161(11):3061–3072. doi: 10.1007/s00705-016-2993-6
  18. Tomo S, Banerjee M, Sharma P, Garg M. Does dehydroepiandrosterone sulfate have a role in COVID-19 prognosis and treatment? Endocr Regul. 2021;55(3):174–181. doi: 10.2478/enr-2021-0019
  19. Vecchione MB, Laufer N, Sued O, et al. 7-oxo-DHEA enhances impaired M. tuberculosis-specific T cell responses during HIV-TB coinfection. J Biomed Sci. 2020;27(1):20. doi: 10.1186/s12929-019-0604-z
  20. Imran M, Zhang L, Zheng B, et al. Screening of novel synthetic derivatives of dehydroepiandrosterone for antivirals against flaviviruses infections. Virol Sin. 2022;37(1):94–106. doi: 10.1016/j.virs.2022.01.007
  21. Seledcova NV, Honina NA, Pasman NM, Chernyh ER. Role of dehydroepiandrosteron in regulation of immunocompetent cells functional activity: literature review. Bjulleten' Sibirskogo otdelenija Rossijskoj akademii medicinskih nauk. 2007;27(1):40–46. EDN: HYRMAJ
  22. Prall SP, Muehlenbein MP. DHEA modulates immune function: a review of evidence. Vitam Horm. 2018;108:125–144. doi: 10.1016/bs.vh.2018.01.023
  23. Lee YH, Suk C, Shin SI, Hong JY. Salivary cortisol, dehydroepiandrosterone, and chromogranin A levels in patients with gingivitis and periodontitis and a novel biomarker for psychological stress. Front Endocrinol (Lausanne). 2023;14:1147739. doi: 10.3389/fendo.2023.1147739
  24. Cornejo Ulloa P, Krom BP, van der Veen MH. Sex steroid hormones as a balancing factor in oral host microbiome interactions. Front Cell Infect Microbiol. 2021;11:714229. doi: 10.3389/fcimb.2021.714229
  25. Dolomatov SI, Zukow W, Atmazhov ID, et al. The use of hormones indicators in human saliva in diagnosing parodontitis in pregnant women. Indian J Hum Genet. 2012;18(3):305–309. doi: 10.4103/0971-6866.107982
  26. Gavate ND, Shetty S, Nayak RS, et al. Assessment of dehydroepiandrosterone sulphate (DHEAS) and cortisol levels in saliva and their correlation to cervical vertebrae maturation method in males and females at different growth stages: a clinical study. Dental Press J Orthod. 2023;28(4):e2322277. doi: 10.1590/2177-6709.28.4.e2322277.oar
  27. Wang YD, Tao MF, Cheng WW, et al. Dehydroepiandrosterone indirectly inhibits human osteoclastic resorption via activating osteoblastic viability by the MAPK pathway. Chin Med J (Engl). 2012;125(7):1230–1235.
  28. Bentley C, Hazeldine J, Greig C, et al. Dehydroepiandrosterone: a potential therapeutic agent in the treatment and rehabilitation of the traumatically injured patient. Burns Trauma. 2019;7:26. doi: 10.1186/s41038-019-0158-z
  29. Qiu X, Gui Y, Xu Y, et al. DHEA promotes osteoblast differentiation by regulating the expression of osteoblast-related genes and Foxp3(+) regulatory T cells. Biosci Trends. 2015;9(5):307–314. doi: 10.5582/bst.2015.01073
  30. Okamoto K, Kiga N, Shinohara Y, et al. Effect of interleukin-1beta and dehydroepiandrosterone on the expression of lumican and fibromodulin in fibroblast-like synovial cells of the human temporomandibular joint. Eur J Histochem. 2015;59(1):2440. doi: 10.4081/ejh.2015.2440
  31. Lavaee F, Rezazadeh F, Saki N, Tavazo Z, Baghaei S. Evaluation of sex hormone levels in patients with pemphigus vulgaris in comparison to the healthy population. Biomed Res Int. 2021;2021:9947706. doi: 10.1155/2021/9947706
  32. Yousefi B, Rastin M, Hatef MR, et al. In vitro modulatory effect of dehydroepiandrosterone sulfate on apoptosis and expression of apoptosis-related genes in patients with systemic lupus erythematosus. J Cell Physiol. 2019;234(8):12676–12684. doi: 10.1002/jcp.27878
  33. Krysiak R, Szkróbka W, Okopień B. Dehydroepiandrosterone potentiates the effect of vitamin D on thyroid autoimmunity in euthyroid women with autoimmune thyroiditis: A pilot study. Clin Exp Pharmacol Physiol. 2021;48(2):195–202. doi: 10.1111/1440-1681.13410
  34. Sawalha AH, Kovats S. Dehydroepiandrosterone in systemic lupus erythematosus. Curr Rheumatol Rep. 2008;10(4):286–291. doi: 10.1007/s11926-008-0046-1
  35. Trokovic N, Pöllänen R, Porola P, et al. Exosomal secretion of death bullets: a new way of apoptotic escape? Am J Physiol Endocrinol Metab. 2012;303(8):E1015-E1024. doi: 10.1152/ajpendo.00139.2012
  36. Ciesielska A, Kusiak A, Ossowska A, Grzybowska ME. Changes in the oral cavity in menopausal women — a narrative review. Int J Environ Res Public Health. 2021;19(1):253. doi: 10.3390/ijerph19010253
  37. Wang L, Zhu L, Yao Y, et al. Role of hormone replacement therapy in relieving oral dryness symptoms in postmenopausal women: a case control study. BMC Oral Health. 2021;21(1):615. doi: 10.1186/s12903-021-01966-6
  38. Mills SJ, Ashworth JJ, Gilliver SC, et al. The sex steroid precursor DHEA accelerates cutaneous wound healing via the estrogen receptors. J Invest Dermatol. 2005;125(5):1053–1062. doi: 10.1111/j.0022-202X.2005.23926.x
  39. Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2018;25(11):1339–1353. doi: 10.1097/GME.0000000000001238
  40. Martel C, Labrie F, Archer DF, et al. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5 mg intravaginal prasterone for 12 weeks. J Steroid Biochem Mol Biol. 2016;159:142–153. doi: 10.1016/j.jsbmb.2016.03.016
  41. Barton DL, Shuster LT, Dockter T, et al. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance). Support Care Cancer. 2018;26(4):1335–1343. doi: 10.1007/s00520-017-3960-9
  42. Matarazzo MG, Sarpietro G, Fiorito D, et al. Intravaginal 6.5 mg prasterone administration in postmenopausal women with overactive bladder syndrome: A pilot study. Eur J Obstet Gynecol Reprod Biol. 2021;263:67–71. doi: 10.1016/j.ejogrb.2021.06.009
  43. Williams MR, Dawood T, Ling S, et al. Dehydroepiandrosterone increases endothelial cell proliferation in vitro and improves endothelial function in vivo by mechanisms independent of androgen and estrogen receptors. J Clin Endocrinol Metab. 2004;89(9):4708–4715. doi: 10.1210/jc.2003-031560
  44. Li LJ, Li C, Chang PM, et al. Dehydroepiandrosterone (DHEA) sensitizes irinotecan to suppress head and neck cancer stem-like cells by downregulation of WNT signaling. Front Oncol. 2022;12:775541. doi: 10.3389/fonc.2022.775541
  45. Cao J, Li L, Yao Y, et al. Dehydroepiandrosterone exacerbates nigericin-induced abnormal autophagy and pyroptosis via GPER activation in LPS-primed macrophages. Cell Death Dis. 2022;13(4):372. doi: 10.1038/s41419-022-04841-6

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Research design.

Download (317KB)
Indexing metadata

Copyright (c) 2024 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия  ПИ № ФС 77 - 86296 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80632 от 15.03.2021 г.